ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Persistent Sexual Dysfunction After Finasteride
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 222142" data-attributes="member: 13851"><p><strong>VASCULAR, NEUROLOGIC, AND HORMONAL ABNORMALITIES IN MEN WITH PERSISTENT SEXUAL DYSFUNCTION AFTER DISCONTINUATION OF FINASTERIDE (2022)</strong></p><p><em>Marvin Carlisle, Maria Uloko, Alyssa Yee, Sue Goldstein, and Irwin Goldstein</em></p><p></p><p></p><p><strong>Abstract</strong></p><p><strong></strong></p><p><strong>INTRODUCTION AND OBJECTIVE:</strong></p><p></p><p><em>Persistent sexual side effects have been repeatedly reported in men after discontinuation of (DC) Finasteride (FIN), including ED, orgasmic dysfunction, and/or genital anhedonia/anesthesia. Khera et al (2020) reported persistent physical sequelae including penile vascular changes in 25 men after DC FIN. The purpose of this study is to replicate Khera’s research findings in a larger population with an analysis of vascular, neurologic, and hormonal testing routinely performed in our clinic.</em></p><p></p><p><strong>METHODS:</strong></p><p></p><p><em>A review of charts (2015-2020) was performed on men who DC FIN and had persistent sexual complaints. Our patient population had: normal sexual function (SF) prior to FIN use; experienced changes in SF within 6 months of DC FIN, and changes persisted > 6 mo. Information collected included sexual function history, current symptoms, validated instruments (IIEF, SDS-R, PSS, McGill Pain Score, PHQ-9), hormone blood test values, data from grayscale/Doppler ultrasound during pharmacological erection (15.4 MHz probe; Aixplorer® Ultrasound) and Quantitative Sensory Testing (QST).</em></p><p></p><p><strong>RESULTS:</strong></p><p></p><p><em>91 patients (median age 39, IQR 32-46) met inclusion criteria, 9.6% of men evaluated during this period. The most common SF symptom was ED in 95% (87/91). The mean IIEF-EF score was 14 ± 8.63 (n=81), consistent with severe (43%), mild-moderate (23%), moderate (12%), and mild (10%) ED. 57 underwent grayscale/Doppler ultrasound; 77% exhibited abnormal erectile tissue inhomogeneity. Mean cavernosal artery PSV/EDV values (n=61) were left 30.4±18.02/0.76±2.86 cm/sec and right 29.63±14.97/0.60±1.89 cm/sec, respectively. Concomitant orgasmic dysfunction and genital anhedonia/anesthesia were noted in 57% and 48%, respectively. These patients underwent QST testing (n=65) and 60% had abnormal results. On presentation, 30% had DHT ≤30 ng/dl, 16% had testosterone (T) ≤350 ng/dl, and 9% had calculated free T ≤6 ng/dl.</em></p><p></p><p><strong>CONCLUSIONS:</strong></p><p></p><p><em><strong>In a large series, we replicated Khera’s findings of persistent physical sequelae associated with changes in SF in men after DC FIN. While more research is needed, this population is young, ED is most often severe, and testing shows a high prevalence of vascular, neurologic, and hormonal pathologies.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 222142, member: 13851"] [B]VASCULAR, NEUROLOGIC, AND HORMONAL ABNORMALITIES IN MEN WITH PERSISTENT SEXUAL DYSFUNCTION AFTER DISCONTINUATION OF FINASTERIDE (2022)[/B] [I]Marvin Carlisle, Maria Uloko, Alyssa Yee, Sue Goldstein, and Irwin Goldstein[/I] [B]Abstract INTRODUCTION AND OBJECTIVE:[/B] [I]Persistent sexual side effects have been repeatedly reported in men after discontinuation of (DC) Finasteride (FIN), including ED, orgasmic dysfunction, and/or genital anhedonia/anesthesia. Khera et al (2020) reported persistent physical sequelae including penile vascular changes in 25 men after DC FIN. The purpose of this study is to replicate Khera’s research findings in a larger population with an analysis of vascular, neurologic, and hormonal testing routinely performed in our clinic.[/I] [B]METHODS:[/B] [I]A review of charts (2015-2020) was performed on men who DC FIN and had persistent sexual complaints. Our patient population had: normal sexual function (SF) prior to FIN use; experienced changes in SF within 6 months of DC FIN, and changes persisted > 6 mo. Information collected included sexual function history, current symptoms, validated instruments (IIEF, SDS-R, PSS, McGill Pain Score, PHQ-9), hormone blood test values, data from grayscale/Doppler ultrasound during pharmacological erection (15.4 MHz probe; Aixplorer® Ultrasound) and Quantitative Sensory Testing (QST).[/I] [B]RESULTS:[/B] [I]91 patients (median age 39, IQR 32-46) met inclusion criteria, 9.6% of men evaluated during this period. The most common SF symptom was ED in 95% (87/91). The mean IIEF-EF score was 14 ± 8.63 (n=81), consistent with severe (43%), mild-moderate (23%), moderate (12%), and mild (10%) ED. 57 underwent grayscale/Doppler ultrasound; 77% exhibited abnormal erectile tissue inhomogeneity. Mean cavernosal artery PSV/EDV values (n=61) were left 30.4±18.02/0.76±2.86 cm/sec and right 29.63±14.97/0.60±1.89 cm/sec, respectively. Concomitant orgasmic dysfunction and genital anhedonia/anesthesia were noted in 57% and 48%, respectively. These patients underwent QST testing (n=65) and 60% had abnormal results. On presentation, 30% had DHT ≤30 ng/dl, 16% had testosterone (T) ≤350 ng/dl, and 9% had calculated free T ≤6 ng/dl.[/I] [B]CONCLUSIONS:[/B] [I][B]In a large series, we replicated Khera’s findings of persistent physical sequelae associated with changes in SF in men after DC FIN. While more research is needed, this population is young, ED is most often severe, and testing shows a high prevalence of vascular, neurologic, and hormonal pathologies.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Persistent Sexual Dysfunction After Finasteride
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top